RAINBOWFISH: Preliminary efficacy and safety data in risdiplam-treated infants with presymptomatic SMA


Clinical Trials

Poster Number: 76


Richard Finkel, MD, St. Jude Children’s Research Hospital, Memphis, TN, USA., Michelle A. Farrar, MD, PhD, Sydney Children’s Hospital Network and UNSW Medicine, UNSW Sydney, Dmitry Vlodavets, Russian National Research Medical University, Edmar Zanoteli, Department of Neurology, Faculdade de Medicina, Universidade de São Paulo (FMUSP), Mohammad Al-Muhaizea, Department of Neurosciences, King Faisal Specialist Hospital & Research Center-Riyadh, Leslie Nelson, PT, PhD, UT Southwestern Medical Center, Alexandra Prufer, Federal Uni Rio de Janeiro, Laurent Servais, I-Motion Institute, Hôpital Armand Trousseau, Yi Wang, Children's Hospital of Fudan University, Carolyn Fisher, Roche Products Ltd, Marianne Gerber, MD, Pharma Development, Safety, F. Hoffmann-La Roche Ltd, Ksenija Gorni, MD, Heidemarie Kletzl, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Laura Palfreeman, Roche Products Ltd, Renata S Scalco, Pharma Development Neurology, F. Hoffmann-La Roche Ltd, Enrico Bertini, Department of Neurosciences and Neurorehabilitation, Bambino Gesù Children’s Research Hospital IRCCS

Spinal muscular atrophy (SMA) is a severe, progressive neuromuscular disease caused by reduced levels of survival of motor neuron (SMN) protein due to deletions and/or mutations of the SMN1 gene. A second gene, SMN2, produces only low levels of functional SMN protein. Risdiplam (EVRYSDI®) is a centrally and peripherally distributed, oral SMN2 pre?mRNA splicing modifier that has been approved by the FDA for the treatment of patients with SMA aged 2 months and older.

RAINBOWFISH (NCT03779334) is an open-label, single-arm, multicenter study that is actively enrolling infants with genetically diagnosed, presymptomatic SMA from birth–6 weeks of age (at first dose), regardless of SMN2 copy number. The primary analysis will be conducted at 12 months in infants with two SMN2 copies and compound muscle action potential (CMAP) amplitude ?1.5mV at baseline.

RAINBOWFISH aims to determine the efficacy, safety and pharmacokinetics (PK)/pharmacodynamics of risdiplam in infants with genetically diagnosed, presymptomatic SMA.

The primary endpoint is the proportion of infants sitting without support for ?5 seconds (assessed by item 22 of the Gross Motor Scale of the Bayley Scales of Infant and Toddler Development, Third Edition). Secondary endpoints include the development of clinically manifested SMA, survival and permanent ventilation, achievement of motor milestones, motor function, growth measures, nutritional status, CMAP, PK, and safety monitoring.

As of the data cut-off (20 February 2021), the median age at first dose was 28.5 days (range: 16–40 days) for the first 12 enrolled infants. No treatment-related serious adverse events were reported in infants treated for up to 18.1 months. Efficacy data from infants receiving risdiplam for ?12 months (n=5) demonstrated that these infants reached a Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders score of ?60 and maintained swallowing and feeding abilities. We will report updated baseline demographics and safety data in enrolled infants and efficacy data in infants who have received risdiplam for ?12 months.

RAINBOWFISH will provide valuable information about outcomes following presymptomatic administration of risdiplam and will help determine the dose for infants aged <2 months. Recruitment is ongoing worldwide.